Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. develops biotechnology products. It focuses on developing Oxycyte, a product alternative to transfused blood for use in surgical and similar medical situations. Oxycyte blood substitute product is a perfluorocarbon emulsified with water and a surfactant, which is provided to the patient intravenously. The properties of perfluorocarbon enable the product to gather oxygen from the lungs and transport the oxygen through the body releasing it along the way. Oxycyte is intended as a transfusion substitute for blood transfusion that ordinarily would be applied in cases of trauma, surgery (emergency and elective), unexpected blood loss, and other general medical applications. The company also develops Fluorovent, an oxygen exchange fluid for facilitating the treatment of lung conditions; and a biosensor implant product that uses an enzyme process for measuring the glucose level in subcutaneous fluid. In addition, it holds patents pertaining to the use and application of perfluorocarbons as gas transport agents in blood substitutes and liquid ventilation. The company, formerly known as Synthetic Blood International, Inc., was founded in 1967 and is based in Costa Mesa, California.